个人文章:牛皮和肥胖:优化药物治疗和生活方式干预措施
Journal of drugs in dermatology : JDD
|January 6, 2025
概括
肥胖症复杂化了牛皮的治疗,但像布罗达卢马布这样的生物药物在BMI范围内表现出一致的疗效. 减肥干预也可以改善肥胖患者的牛皮严重程度.
科学领域:
- 皮肤病学 皮肤病学
- 代谢疾病 代谢疾病
- 免疫学 免疫学 免疫学
背景情况:
- 肥胖 (BMI ≥30 kg/m2) 是一种与慢性炎症相关的代谢疾病.
- 肥胖是牛皮的并发症,是一种慢性自身免疫性皮肤疾病.
- 肥胖症中的脂肪细胞释放出促炎性细胞因子,可能会加剧牛皮病原体的发生.
研究的目的:
- 对肥胖患者的牛皮治疗生物疗法的疗效进行审查.
- 讨论肥胖对系统性牛皮治疗药理学的影响.
- 探索减肥干预措施在治疗患有牛皮的肥胖患者中的作用.
主要方法:
- 临床试验和真实世界关于牛皮生物治疗的数据的审查.
- 对评估肥胖牛皮患者减肥干预措施 (例如GLP-1激动剂,减肥手术) 的研究进行分析.
- 对肥胖个体的全身疗法的药理动力学考虑的检查.
主要成果:
- 生物疗法,特别是IL-17和IL-23抑制剂,对于包括肥胖患者在内的泛性斑块牛皮是有效的.
- 布罗达卢马布 (IL-17受体抑制剂) 在各种BMI类别中表现出一致的疗效.
- 减肥干预措施显示了与肥胖管理一起改善牛皮病严重程度的潜力.
结论:
- 生物治疗是患有牛皮的肥胖患者的关键治疗选择.
- 对于一般斑块牛皮的有效生物药物通常在肥胖人群中表现良好.
- 整合减肥策略可能会提高患有牛皮的肥胖个体的整体治疗结果.
相关概念视频
Cancer Prevention
6.5K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.5K
Drug Dosing: Obese Patients
368
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
368
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
440
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
Coronary Artery Disease IV: Preventive Measures
890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741


